Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H12O3S.C4H11NO3 |
| Molecular Weight | 381.443 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(CO)(CO)CO.CC(C(O)=O)C1=CC=C(S1)C(=O)C2=CC=CC=C2
InChI
InChIKey=PDWBZKWQZFGXGU-UHFFFAOYSA-N
InChI=1S/C14H12O3S.C4H11NO3/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10;5-4(1-6,2-7)3-8/h2-9H,1H3,(H,16,17);6-8H,1-3,5H2
| Molecular Formula | C4H11NO3 |
| Molecular Weight | 121.135 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H12O3S |
| Molecular Weight | 260.308 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Tiaprofenic acid is a non-steroidal, anti-inflammatory, analgesic compound, which nonselectively inhibits cyclooxygenase protein. Tiaprofenic acid was approved in Europe for the symptomatic relief of arthritis, ankylosing spondylitis and other inflammatory-rheumatic disorders as well as the painful conditions after injury.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094253 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | SURGAM Approved UseSymptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury. |
|||
| Primary | SURGAM Approved UseSymptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury. |
|||
| Palliative | SURGAM Approved UseSymptomatic treatment of pain and inflammation in acute arthritis (including gout attack), chronic arthritis (rheumatoid arthritis in particular), ankylosing spondylitis and other inflammatory-rheumatic spinal disorders, irritation in degenerative joint and spine diseases (arthritis and spondylarthritis), inflammatory soft tissue rheumatic diseases, painful swelling or inflammation after injury. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Hepatotoxicity to several nonsteroidal anti-inflammatory drugs with diclofenac induced histological changes. | 1992 Mar |
|
| Directed control of electroosmotic flow in nonaqueous electrolytes using poly(ethylene glycol) coated capillaries. | 2001 |
|
| Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. | 2001 |
|
| [New technologies in laparoscopic surgery]. | 2001 Mar |
|
| Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients. | 2001 Nov |
|
| [Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases]. | 2001 Oct |
|
| [Tuberculous osteitis of the malar bone]. | 2002 |
|
| Fixed drug eruption due to tiaprofenic acid. | 2002 Dec |
|
| The role of the Australian Adverse Drug Reactions Advisory Committee (ADRAC) in monitoring drug safety. | 2002 Dec 27 |
|
| [Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000]. | 2002 Jan-Feb |
|
| Do NSAIDs affect the progression of osteoarthritis? | 2002 Jun |
|
| Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules. | 2003 Mar |
|
| The modulation of intra-articular inflammation, cartilage matrix and bone loss in mono-articular arthritis induced by heat-killed Mycobacterium tuberculosis. | 2005 |
|
| Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. | 2005 Nov 29 |
|
| Effects of co-administered dexamethasone and diclofenac potassium on pain, swelling and trismus following third molar surgery. | 2005 Nov 7 |
|
| [Patterns of non steroidal anti-inflammatory drug use in ambulatory care]. | 2006 Mar-Apr |
|
| Use of the yeast Saccharomyces cerevisiae as a pre-screening approach for assessment of chemical-induced phototoxicity. | 2006 Sep |
|
| Activity and potential role of licofelone in the management of osteoarthritis. | 2007 |
|
| Acute NSAID-related transmural duodenitis and extensive duodenal ulceration. | 2007 Nov |
|
| Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis. | 2008 |
|
| The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. | 2008 Apr 1 |
|
| Direct enantioselective HPLC monitoring of lipase-catalyzed kinetic resolution of tiaprofenic acid in nonstandard HPLC organic solvents. | 2008 Aug |
|
| Cholesterol-diaryl ketone stereoisomeric dyads as models for "clean" type I and type II photooxygenation mechanisms. | 2008 Mar 7 |
|
| Photodegradation mechanism of nonsteroidal anti-inflammatory drugs containing thiophene moieties: suprofen and tiaprofenic acid. | 2009 Aug 13 |
|
| An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model. | 2009 Jul 22 |
|
| Hemorrhagic cystitis: A challenge to the urologist. | 2010 Apr |
|
| Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
The recommended daily dose range for adults is 600 mg tiaprofen acid per day divided into 2 doses.
Route of Administration:
Oral
Human osteoarthritic cartilage was treated with therapeutic doses of tiaprofenic acid (26 micrograms/ml; 2.6 micrograms/ml) in order to test the effect of the drug on the proteoglycan metabolism (catabolism and synthesis) and chondrocyte ultrastructure. The drug suppresed the proteoglycan metabolism by 38%.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:37:21 GMT 2023
by
admin
on
Sat Dec 16 08:37:21 GMT 2023
|
| Record UNII |
ZR3VFO4VD3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
62715-04-2
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY | |||
|
6454459
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY | |||
|
ZR3VFO4VD3
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY | |||
|
DTXSID60978337
Created by
admin on Sat Dec 16 08:37:21 GMT 2023 , Edited by admin on Sat Dec 16 08:37:21 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |